Jump to main content
Jump to site search

Issue 10, 2019
Previous Article Next Article

Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma

Author affiliations

Abstract

Metabolic glycoengineering of unnatural monosaccharides provides a facile method to label cancer cells with chemical tags for glycan imaging and cancer targeting. Multiple types of monosaccharides have been utilized for metabolic cell labeling. However, the comparison of different types of monosaccharides in labeling efficiency and selectivity has not been reported. In this study, we compared N-azidoacetylgalactosamine (GalAz) and N-azidoacetylmannosamine (ManAz) for metabolic labeling of HepG2 hepatocellular carcinoma in vitro and in vivo. GalAz showed higher labeling efficiency at low concentrations, and outperformed ManAz in metabolic labeling of HepG2 tumors in vivo. GalAz mediated labeling of HepG2 tumors with azido groups significantly improved the tumor accumulation of dibenzocyclooctyne (DBCO)–Cy5 and DBCO–doxorubicin conjugate via efficient Click chemistry. This study, for the first time, uncovered the distinct labeling efficiency and selectivity of different unnatural monosaccharides in liver cancers.

Graphical abstract: Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma

Back to tab navigation

Supplementary files

Article information


Submitted
10 Jun 2019
Accepted
04 Jul 2019
First published
31 Jul 2019

Biomater. Sci., 2019,7, 4166-4173
Article type
Paper

Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma

H. Wang, Y. Liu, M. Xu and J. Cheng, Biomater. Sci., 2019, 7, 4166
DOI: 10.1039/C9BM00898E

Social activity

Search articles by author

Spotlight

Advertisements